Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$250.63
-0.1%
$234.73
$160.36
▼
$261.00
$37.02B0.11.20 million shs551,657 shs
Eisai Co., Ltd. stock logo
ESALY
Eisai
$61.51
-2.1%
$61.51
$36.88
▼
$73.90
$17.64B0.3160,916 shs331,800 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,387.42
-2.0%
$1,253.71
$850.51
▼
$1,475.25
$1.30T0.42.95 million shs1.69 million shs
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$181.63
-1.9%
$175.74
$141.97
▼
$192.32
$48.56B0.5211.08 million shs15.38 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
-0.34%-0.97%+7.80%+13.19%+52.29%
Eisai Co., Ltd. stock logo
ESALY
Eisai
0.00%0.00%0.00%0.00%0.00%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-1.29%-1.39%+12.29%+10.31%+38.04%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
-1.41%-1.93%+4.83%+5.44%+22.11%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$250.63
-0.1%
$234.73
$160.36
▼
$261.00
$37.02B0.11.20 million shs551,657 shs
Eisai Co., Ltd. stock logo
ESALY
Eisai
$61.51
-2.1%
$61.51
$36.88
▼
$73.90
$17.64B0.3160,916 shs331,800 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,387.42
-2.0%
$1,253.71
$850.51
▼
$1,475.25
$1.30T0.42.95 million shs1.69 million shs
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$181.63
-1.9%
$175.74
$141.97
▼
$192.32
$48.56B0.5211.08 million shs15.38 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
-0.34%-0.97%+7.80%+13.19%+52.29%
Eisai Co., Ltd. stock logo
ESALY
Eisai
0.00%0.00%0.00%0.00%0.00%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-1.29%-1.39%+12.29%+10.31%+38.04%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
-1.41%-1.93%+4.83%+5.44%+22.11%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biogen Inc. stock logo
BIIB
Biogen
2.67
Moderate Buy$254.412.10% Upside
Eisai Co., Ltd. stock logo
ESALY
Eisai
0.00
N/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.83
Moderate Buy$1,422.002.33% Upside
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
2.72
Moderate Buy$182.580.17% Upside

Current Analyst Ratings Breakdown

Latest BIIB, LLY, XLV, and ESALY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/18/2026
Biogen Inc. stock logo
BIIB
Biogen
Reiterated RatingBuy
11/17/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform$1,600.00
11/16/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,400.00 ➝ $1,550.00
11/13/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UpgradeBuy (B) ➝ Buy (B+)
11/12/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DowngradeBuy ➝ Hold
11/9/2026
Biogen Inc. stock logo
BIIB
Biogen
Reiterated RatingOverweight$245.00 ➝ $305.00
11/9/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,610.00 ➝ $1,700.00
11/2/2026
Biogen Inc. stock logo
BIIB
Biogen
Boost Price TargetBuy$280.00 ➝ $300.00
11/2/2026
Biogen Inc. stock logo
BIIB
Biogen
Boost Price TargetBuy$251.00 ➝ $270.00
11/2/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,440.00 ➝ $1,600.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DowngradeBuy (B+) ➝ Buy (B)
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biogen Inc. stock logo
BIIB
Biogen
$9.89B3.72$22.41 per share11.12$128.01 per share1.95
Eisai Co., Ltd. stock logo
ESALY
Eisai
$6.74B2.62$2.68 per share22.94$23.94 per share2.57
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B20.06$24.40 per share56.95$42.81 per share32.46
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$2.34106.3815.632.853.37%9.38%5.69%2/5/2027 (Estimated)
Eisai Co., Ltd. stock logo
ESALY
Eisai
$426.79M$0.8770.7051.692.464.11%3.86%2.50%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$30.8145.0327.401.7131.90%86.76%22.03%2/3/2027 (Estimated)
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/A33.45N/AN/AN/AN/AN/AN/A

Latest BIIB, LLY, XLV, and ESALY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2026Q3 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.71$7.48+$1.77$7.22$22.58 billion$24.40 billion
10/28/2026Q3 2026
Biogen Inc. stock logo
BIIB
Biogen
$1.99$2.62+$0.63-$0.14$2.63 billion$2.80 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Eisai Co., Ltd. stock logo
ESALY
Eisai
$0.881.43%N/A101.15%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.50%+15.18%22.46%11 Years
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$2.551.40%N/AN/AN/A

Latest BIIB, LLY, XLV, and ESALY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.48%11/13/202611/13/202612/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biogen Inc. stock logo
BIIB
Biogen
0.39
1.95
1.37
Eisai Co., Ltd. stock logo
ESALY
Eisai
0.10
2.20
1.77
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.17
1.39
1.00
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Eisai Co., Ltd. stock logo
ESALY
Eisai
0.03%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/A

Insider Ownership

CompanyInsider Ownership
Biogen Inc. stock logo
BIIB
Biogen
0.25%
Eisai Co., Ltd. stock logo
ESALY
Eisai
N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.82 million147.45 millionOptionable
Eisai Co., Ltd. stock logo
ESALY
Eisai
11,322286.77 millionN/ANot Optionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000940.74 million939.43 millionOptionable
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/A267.32 millionN/ANot Optionable

Recent News About These Companies

Which Sectors Do Well Amid 5% 10-Year Treasury Yields?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Biogen stock logo

Biogen NASDAQ:BIIB

$250.62 -0.17 (-0.07%)
As of 03:25 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Eisai stock logo

Eisai OTCMKTS:ESALY

$61.51 -1.33 (-2.11%)
As of 01/30/2023

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,388.28 -27.27 (-1.93%)
As of 03:25 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Health Care Select Sector SPDR Fund stock logo

Health Care Select Sector SPDR Fund NYSEARCA:XLV

$181.68 -3.56 (-1.92%)
As of 03:25 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Health Care Select Sector SPDR Fund (the Fund) seeks to closely match the returns and characteristics of the S&P Health Care Select Sector Index (the Index). The companies included in the Index are selected on the basis of general industry classification from a universe of companies defined by the Standard & Poor's 500 Composite Stock Index (S&P 500). The Health Care Select Sector Index includes companies from the industries, such as pharmaceuticals, healthcare providers and services, healthcare equipment and supplies, biotechnology, life sciences tools and services, and healthcare technology. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. State Street Global Advisors acts as the Fund's investment manager.